Seminari di Ematologia Oncologica - Società Italiana di Ematologia
Seminari di Ematologia Oncologica - Società Italiana di Ematologia
Seminari di Ematologia Oncologica - Società Italiana di Ematologia
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
26 <strong>Seminari</strong> <strong>di</strong> <strong>Ematologia</strong> <strong>Oncologica</strong><br />
pre-ASCT e sia nei pazienti non can<strong>di</strong>dabili a<br />
HDC+ASCT.<br />
n BIBLIOGRAFIA<br />
1. Greiner TC, Medeiros LJ, Jaffe ES. Non-Hodgkin’s lymphoma.<br />
Cancer. 1995; 75: 370-80.<br />
2. The non-Hodgkin's Lymphoma Classification Project.<br />
A clinical evaluation of the International Lymphoma<br />
Study Group classification of non-Hodgkin's<br />
Lymphoma. Blood. 1997; 89: 3909-18.<br />
3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H,<br />
Bouabdallah R, et al. CHOP chemotherapy plus rituximab<br />
compared with CHOP alone in elderly patients<br />
with <strong>di</strong>ffuse large-B-cell lymphoma. N Engl J Med.<br />
2002; 346: 235-42.<br />
4. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G,<br />
Plantier I, Castaigne S, et al. Blood. 2010; 116: 2040-<br />
45.<br />
5. Pfreundschuh M, Schubert J, Ziepert M, Schmits R,<br />
Mohren M, Lengfelder E, et al. Six versus eight cycles<br />
of bi-weekly CHOP-14 with or without Rituximab in elderly<br />
patients with aggressive CD20+ B-Cell<br />
Lymphomas: a randomised controlled trial (RICOVER-<br />
60). Lancet Oncol. 2008; 9: 105-16.<br />
6. Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA,<br />
Gisselbrecht C, et al. High-dose chemotherapy with<br />
autologous stem cell support in first-line treatment of<br />
aggressive non-Hodgkin lymphoma - Results of a comprehensive<br />
meta-analysis. Cancer Treat Rev. 2007; 33:<br />
338-46.<br />
7. Shipp MA, Harrington DP: A pre<strong>di</strong>ctive model for<br />
aggressive NHL: the International non-Hodgkin’s lymphoma<br />
prognostic factors project. N Engl J Med. 1993;<br />
329: 987-94.<br />
8. Ziepert M, Hasenclever D, Kuhnt E, Glass B,<br />
Schmitz N, Pfrendschuh M, et al. Standard international<br />
prognostic index remains a valid pre<strong>di</strong>ctor of<br />
outcome for patients with aggressive CD20+ B-cell<br />
lymphoma in the rituximab era. J Clin Oncol. 2010;<br />
28: 2373-80.<br />
9. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD,<br />
Specht L, Horning SJ, et al. Revised response criteria<br />
for malignant lymphoma. J Clin Oncol. 2007; 25:<br />
579-86.<br />
10. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj<br />
K, et al. [18-F]fluoro-2-deoxy-D-glucose positron<br />
emission tomography in aggressive lymphoma: an early<br />
prognostic tool for pre<strong>di</strong>cting patients outcome.<br />
Blood. 2005; 106: 1376-81.<br />
11. Cashen A, Dehdashti F, Luo J, Bartlett NL. Poor pre<strong>di</strong>ctive<br />
value of FDG-PET/CT performed after 2 cycles<br />
of R-CHOP in patients with Diffuse Large B-Cell<br />
Lymphoma (DLCL). Blood. 2008; 112: 371.<br />
12. Vitolo U, Chiappella A, Bellò M, Passera R, Botto B,<br />
Castellano G, et al. The outcome of patients with<br />
Diffuse Large B-Cell Lymphoma (DLBCL) treated with<br />
Rituximab-CHOP (R-CHOP) is not pre<strong>di</strong>cted by 18-<br />
FDG-Positron Emission Tomography/Computerized<br />
Tomography (PET) performed at interme<strong>di</strong>ate incourse<br />
evaluation, but only by PET assessed at the end<br />
of therapy. Blood. 2010; 116: 2819.<br />
13. World Health Organization. WHO Classification of<br />
Tumours of Haematopoietic and Lymphoid Tissues.<br />
Geneva, Switzerland: WHO Press. 2008.<br />
14. Alizadeh AA, Elsen MB, Davis RE, et al. Distinct types<br />
of <strong>di</strong>ffuse large B-cell lymphoma identified by gene<br />
expression profiling. Nature. 2000; 403: 504-11.<br />
15. Hans CP, Weisenburger DD, Greiner TC, et al.<br />
Confirmation of the molecular classification of <strong>di</strong>ffuse<br />
large B-cell lymphoma by immunohistochemistry<br />
using a tissue microarray. Blood. 2004; 103: 275-82.<br />
16. Dunleavy K, Pittaluga S, Czuczman MS, et al.<br />
Differential efficacy of bortezomib plus chemotherapy<br />
within molecular subtypes of <strong>di</strong>ffuse large B-cell lymphoma.<br />
Blood. 2009; 113: 6069-76.<br />
17. Rossi D, Rasi S, Franceschetti S, Capello D, Castelli<br />
A, De Paoli L, et al. Analysis of the host pharmacogenetic<br />
background for pre<strong>di</strong>ction of outcome and toxicity<br />
in <strong>di</strong>ffuse large B-cell lymphoma treated with R-<br />
CHOP21. Leukemia. 2009; 23: 1118-26.<br />
18. Rossi D, Rasi S, Di Rocco A, Fabbri A, Forconi F,<br />
Gloghini A, et al. The host genetic background of DNA<br />
repair mechanisms is an independent pre<strong>di</strong>ctor of survival<br />
in <strong>di</strong>ffuse large B-cell lymphoma. Blood 2011; 117<br />
(8): 2405-13.<br />
19. Pfreundschuh M, Trumper L, Osterborg A, Pettengell<br />
R, Trneny M, Imrie K, et al. CHOP-like chemotherapy<br />
plus Rituximab versus CHOP-like chemotherapy alone<br />
in young patients with good-prognosis Diffuse Large-<br />
B-Cell Lymphoma: a randomised controlled trial by the<br />
MabThera International Trial (MInT) Group. Lancet<br />
Oncol. 2006; 7: 379-91.<br />
20. Brusamolino E, Rusconi C, Montalbetti L, Gargantini<br />
L, Uziel L, Pinotti G, et al. Dose-dense R-CHOP-14 supported<br />
by pegfilgrastim in patients with <strong>di</strong>ffuse large<br />
B-cell lymphoma: a phase II study of feasibility and toxicity.<br />
Haematologica. 2006; 91: 496-502.<br />
21. Barosi G, Carella A, Lazzarino M, Marchetti M, Martelli<br />
M, Rambal<strong>di</strong> A, et al. Management of nodal <strong>di</strong>ffuse<br />
large B-cell lymphomas: practice guidelines from the<br />
Italian Society of Hematology, the Italian Society of<br />
Experimental Hematology and the Italian Group for<br />
Bone Marrow Transplantation. Haematologica. 2006;<br />
91: 96-103.<br />
22. Vitolo U, Chiappella A, Angelucci E, Rossi G, Liberati<br />
AM, Cabras MG, et al. Dose-dense and high-dose<br />
chemotherapy plus Rituximab with autologous stem<br />
cell transplantation for primary treatment of <strong>di</strong>ffuse<br />
large-B-cell lymphoma at poor prognosis: a phase II<br />
multicenter study. Haematologica. 2009; 94: 1250-8.<br />
23. Schmitz N, Nickelsen M, Ziepert M, Haenel M,